By acquiring six phytopharmaceuticals of Hexal, DR.KADE strengthens it’s German OTC portfolio. Included are, among others, Femikliman for the treatment of pain in the menopause and Silicur for the protection of the liver.
DR. KADE acquires the Consumer Health business of Takeda Germany, including traditional and well-known brands such as Faktu, Sanostol, Riopan and Buer Lecithin, for the German market.
The pharmacy sales force, DR. KADE Avenda, is founded as a 100% subsidiary of DR. KADE Pharma. The sales force visits approx. 12,000 pharmacies throughout Germany. The focus of discussions is DR. KADE’s OTC product portfolio.
At the site in Konstanz, very modern production premises for hormone production are put into operation, at which, for example, Cliovelle tablets are produced.
Ten years after the launch of the first products in Poland, DR. KADE founds the German-Polish joint venture Kadefarm. The new sales company is situated nearby Poznan.
With Trancopal Dolo and Trancolong, DR. KADE launches two new innovative drugs for the treatment of back pains.
To expand the market position in non-prescription medicine (over-the-counter), DR. KADE begins pharmacy sales with the product ranges Posterisan and KadeFungin.
The joint venture “DR. KADE/BESINS Pharma” with the Belgian company Besins Healthcare is established. Through this cooperation primarily gynaecological drugs are marketed in Germany.
The political change in the East means further expansion for DR. KADE, which is accompanied by the set-up of a pharmaceutical sales team in the new Federal States.
The Berlin site is extended: in the district of Marienfelde a modern pharmaceutical site is build, in which parts of the production and quality control as well as the Marketing, Export and Medical Departments find a new home.
DR. KADE opens an office in the USA as a further international pillar.
The fourth generation of the Lutze family, Arthur Sackler, joins the management of DR. KADE.
With Oekolp, DR. KADE introduces the first low-dose, locally administered oestrogen onto the market.
Due to the dynamic development of business at DR. KADE as well as the uncertain political situation in Berlin, a second site is constructed in Konstanz. Parts of production and quality control, Galenic development, and sales are located here.
With Dr. Marietta Lutze the third generation takes over the management of the family company after the war. Dr. Marietta Lutze-Sackler was awarded the Federal Cross of Merit in 2007 for her work for the company and her social dedication.
The start of a business relationship with the Japanese company Maruho in Osaka revives the export business. The very successful cooperation in proctology remains to this day.
Medical history is written with the haemorrhoid drug Posterisan. The drug, which enjoys success abroad to the current day, is based on an innovative, immunologically active bacterial culture suspension (BCS) – a milestone in development at DR. KADE.
In 2011 DR. KADE celebrated its 125th anniversary – and looks back to a long history: twelve and a half decades, in which the company has continually grown and helped to provide patients a better quality of life.